文章摘要
栾力介,田丽娟.我国药品生产企业信用监管法制建设存在的问题及对策研究[J].中国药事,2024,38(8):853-859
我国药品生产企业信用监管法制建设存在的问题及对策研究
Research on Problems and Countermeasures of Credit Supervision Laws andRegulations Construction of Drug Production Enterprises in China
投稿时间:2023-10-25  
DOI:10.16153/j.1002-7777.20230907
中文关键词: 药品安全  药品生产企业  诚信  信用监管  法制建设
英文关键词: drug safety  drug production enterprises  credibility  credit supervision  laws and regulationsconstruction
基金项目:
作者单位
栾力介 沈阳药科大学工商管理学院沈阳 110016 
田丽娟 沈阳药科大学工商管理学院沈阳 110016 
摘要点击次数: 292
全文下载次数: 322
中文摘要:
      目的:为完善我国药品生产企业信用监管法制建设,提高我国药品生产企业诚信意识,促进诚信生产活动提供建议与参考。方法:通过对我国药品生产企业信用监管法制建设的研究,分析其存在的问题并提出合理化建议。结果与结论:我国药品生产企业信用监管法制建设尚不完善,主要体现在信用奖惩机制尚不健全,联合惩戒机制还不完善;信用等级评定办法缺乏具体和统一的标准;信用信息公开披露的规定不够具体;医药行业协会作用发挥不充分等。基于此,从信用奖惩机制、信用等级评定制度、信用信息公开披露制度与外部支撑体系作用4个方面提出对应的建议,以加强我国药品生产企业信用监管法制建设。
英文摘要:
      Objective: To improve the laws and regulations construction of credit supervision of drug productionenterprises, improve the integrity awareness of drug production enterprises in China, and provide suggestionsand references for promoting integrity production activities. Methods: The existing problems were analyzedand reasonable suggestions were put forward through research on the construction of credit supervision laws andregulations of drug production enterprises in China. Results and Conclusion: China's drug production enterprisecredit supervision laws and regulations construction was not perfect, mainly reflected in the credit reward andpunishment mechanism was not perfect, the joint punishment mechanism was not perfect; the credit rating methodlacked specific and unified standards; the provisions on the disclosure of credit information were not specificenough; the role of the pharmaceutical industry association was not fully played. Based on this, this paper putsforward corresponding suggestions from four aspects: credit reward and punishment mechanism, credit ratingevaluation system, credit information disclosure system and external support system, so as to strengthen the lawsand regulations construction of credit supervision of drug production enterprises in China.
查看全文   查看/发表评论  下载PDF阅读器
关闭